Alkermes, Inc. Earnings Conference Call (Q2 2010)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Nov 5 Calls Today's Calls

Call Details Alkermes, Inc. Earnings Conference Call (Q2 2010) Thu, Nov 5, 2009, 4:30 pm Eastern Listen to the archived event audio About Alkermes, Inc. (NasdaqGS:ALKS) Alkermes, Inc., an integrated biotechnology company, offers extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction, and diabetes. It primarily develops, manufactures, and commercializes VIVITROL, an extended-release Medisorb formulation of naltrexone for the treatment of alcohol dependence, as well as for the treatment of opioid dependence. The company also manufactures RISPERDAL CONSTA, a formulation of risperidone for the treatment of schizophrenia and bipolar disorder. In addition, it is developing Exenatide once weekly for the treatment of type 2 diabetes; ALKS 33, an opioid modulator, which completed phase I randomized, double-blind, and placebo-controlled study for the treatment of addiction, pain, and other nervous system disorders; ALKS 29, an oral combination therapy for the treatment of alcohol dependence; ALKS 27, an inhaled trospium product that is in a phase IIa study for the treatment of chronic obstructive pulmonary disease; and ALKS 36, a co-formulation of an opioid analgesic and RDC-1036 for the treatment of pain. Alkermes, Inc. has collaborative arrangements with Janssen Pharmaceutica, Inc.; Cilag GmbH International; Amylin Pharmaceuticals, Inc.; and Rensselaer Polytechnic Institute. The company was founded in 1987 and is headquartered in Cambridge, Massachusetts. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings